ADC Therapeutics(US:ADCT) Newsfilter·2024-04-04 11:00Core Insights - ADC Therapeutics has completed the dose escalation phase of the LOTIS-7 trial for ZYNLONTA in combination with bispecific antibodies for treating relapsed/refractory B-cell non-Hodgkin lymphoma, showing no dose-limiting toxicities and early signs of anti-tumor activity [1][2][3] Group 1: Trial Details - The LOTIS-7 trial is a Phase 1b open-label study evaluating ZYNLONTA in combination with glofitamab or mosunetuzumab in heavily pre-treated patients [1][3] - In the dose escalation portion, no dose-limiting toxicities, low-grade cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome were observed [2][3] - Enrollment in Part 2 of the trial has begun, focusing on dose expansion with ZYNLONTA at 120 µg/kg and 150 µg/kg [2][3] Group 2: Efficacy and Safety - Early data indicate evidence of anti-tumor activity among the majority of patients, including those with diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma [2][3] - The favorable toxicity profile observed in the trial is encouraging given the unmet medical need in treating relapsed or refractory B-cell non-Hodgkin lymphoma [3] Group 3: Company Overview - ADC Therapeutics is a leader in the field of antibody drug conjugates, with ZYNLONTA receiving accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [8][9] - The company is advancing its proprietary ADC technology and has multiple ADCs in ongoing clinical and preclinical development [8][9]